CA2981969C - Humanized influenza monoclonal antibodies and methods of use thereof - Google Patents

Humanized influenza monoclonal antibodies and methods of use thereof Download PDF

Info

Publication number
CA2981969C
CA2981969C CA2981969A CA2981969A CA2981969C CA 2981969 C CA2981969 C CA 2981969C CA 2981969 A CA2981969 A CA 2981969A CA 2981969 A CA2981969 A CA 2981969A CA 2981969 C CA2981969 C CA 2981969C
Authority
CA
Canada
Prior art keywords
antibody
seq
acid sequence
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2981969A
Other languages
English (en)
French (fr)
Other versions
CA2981969A1 (en
Inventor
Wayne A. Marasco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2981969A1 publication Critical patent/CA2981969A1/en
Application granted granted Critical
Publication of CA2981969C publication Critical patent/CA2981969C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2981969A 2015-04-08 2016-04-08 Humanized influenza monoclonal antibodies and methods of use thereof Active CA2981969C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144729P 2015-04-08 2015-04-08
US62/144,729 2015-04-08
PCT/US2016/026800 WO2016164835A1 (en) 2015-04-08 2016-04-08 Humanized influenza monoclonal antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2981969A1 CA2981969A1 (en) 2016-10-13
CA2981969C true CA2981969C (en) 2023-12-05

Family

ID=55754481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981969A Active CA2981969C (en) 2015-04-08 2016-04-08 Humanized influenza monoclonal antibodies and methods of use thereof

Country Status (9)

Country Link
US (2) US11135282B2 (cg-RX-API-DMAC7.html)
EP (1) EP3280730B1 (cg-RX-API-DMAC7.html)
JP (3) JP6960856B2 (cg-RX-API-DMAC7.html)
KR (1) KR102668588B1 (cg-RX-API-DMAC7.html)
CN (1) CN107750253B (cg-RX-API-DMAC7.html)
AU (2) AU2016246065B2 (cg-RX-API-DMAC7.html)
CA (1) CA2981969C (cg-RX-API-DMAC7.html)
IL (2) IL254951B (cg-RX-API-DMAC7.html)
WO (1) WO2016164835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
WO2015143194A2 (en) * 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2018071913A2 (en) 2016-10-14 2018-04-19 Dana-Farber Cancer Institute, Inc. Modular tetrameric bispecific antibody platform
MX2020007772A (es) * 2018-01-26 2020-09-18 Regeneron Pharma Anticuerpos humanos contra hemaglutinina de influenza.
EP3765070A4 (en) 2018-03-14 2021-12-15 Dana-Farber Cancer Institute, Inc. SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES
SG11202100467VA (en) 2018-08-13 2021-02-25 Regeneron Pharma Therapeutic protein selection in simulated in vivo conditions
CN109448781B (zh) * 2018-11-06 2021-09-14 云南大学 一种流感病毒抗原变化的预测方法
CN111423507B (zh) * 2019-01-10 2022-04-15 中国科学院分子细胞科学卓越创新中心 广谱性中和流感病毒的全人抗体
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
KR20220113749A (ko) * 2019-12-11 2022-08-16 비스테라, 인크. 인플루엔자를 치료하고 예방하는 조성물 및 방법
IL312538A (en) 2021-11-05 2024-07-01 Abviro Llc Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
CN114366809B (zh) * 2022-01-12 2024-07-23 广州瑞贝斯药业有限公司 一种铝纳米晶递送系统及其结合疫苗抗原分子自组装颗粒佐剂疫苗

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CN102448986B (zh) * 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
SI2552485T1 (sl) * 2010-03-26 2017-05-31 Pomona Ricerca S.R.L. Imunoglobulini polne dolžine igg izotipa, sposobni prepoznave heteropodtipskega nevtralizacijskega epitopa na hemagglutininskem izvornem področju in njih uporaba kot zdravilo proti gripi
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
DK2731967T3 (en) 2011-07-14 2017-01-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS
ES2841899T3 (es) * 2011-07-18 2021-07-12 Inst Res Biomedicine Anticuerpos neutralizantes del virus de la influenza A y usos de los mismos
MX350282B (es) * 2011-09-30 2017-09-01 Celltrion Inc Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
JP6386465B2 (ja) * 2012-11-13 2018-09-05 ジェネンテック， インコーポレイテッド 抗ヘマグルチニン抗体及び使用方法
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
US20180099040A1 (en) 2018-04-12
CN107750253A (zh) 2018-03-02
IL254951B (en) 2021-09-30
KR102668588B1 (ko) 2024-05-22
JP2021121204A (ja) 2021-08-26
EP3280730B1 (en) 2024-01-03
AU2021225240A1 (en) 2021-09-30
AU2016246065A1 (en) 2017-10-26
WO2016164835A1 (en) 2016-10-13
IL254951A0 (en) 2017-12-31
CA2981969A1 (en) 2016-10-13
US12076390B2 (en) 2024-09-03
AU2016246065B2 (en) 2021-06-03
IL286208A (en) 2021-10-31
CN107750253B (zh) 2022-10-04
US11135282B2 (en) 2021-10-05
JP6960856B2 (ja) 2021-11-05
US20220054624A1 (en) 2022-02-24
EP3280730C0 (en) 2024-01-03
JP2018518940A (ja) 2018-07-19
KR20170133507A (ko) 2017-12-05
JP2023130499A (ja) 2023-09-20
EP3280730A1 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
US12076390B2 (en) Humanized influenza monoclonal antibodies and methods of use thereof
AU2008338691B2 (en) Antibodies against influenza virus and methods of use thereof
JP2024542158A (ja) ヒト広域交差反応性インフルエンザモノクローナル抗体及びその使用方法
AU2019204310B2 (en) Antibodies against influenza virus and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210315

EEER Examination request

Effective date: 20210315

EEER Examination request

Effective date: 20210315

EEER Examination request

Effective date: 20210315

EEER Examination request

Effective date: 20210315

EEER Examination request

Effective date: 20210315

EEER Examination request

Effective date: 20210315

EEER Examination request

Effective date: 20210315